Ebola Transmission: Difference between revisions
Vgawlik6782 (talk | contribs) |
Vgawlik6782 (talk | contribs) |
||
Line 36: | Line 36: | ||
==References== | ==References== | ||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189988/ Aleksandrowicz, P., A. Marzi, N. Biedenkopf, N. Beimforde, S. Becker et al. "Ebola Virus Enters Host Cells by Macropinocytosis and Clathrin-Mediated Endocytosis". ''The Journal of Infectious Diseases''. 2011. Volume 204. Suppl 3S957-967.] | |||
[http://www.pnas.org/content/early/2012/02/22/1120453109 Bharat T., et al. "Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography". '' Proceedings of the National Academy of Sciences of the United States of America''. 2012. p. 4275-4280.] | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1579243/ Noda, T., H. Ebihara, Y. Muramoto, K. Fujii, A. Takada, et al. "Assembly and Budding of Ebolavirus". ''PLoS Pathogens''. 2006. Volume 2(9).] | |||
[http://www.pnas.org/content/early/2011/11/29/1117715108 Phoolcharoen, Waranyoo, John M. Dye, et al. "A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge". ''Proceedings of the National Academy of Sciences of the United States of America''. 2011. Volume 180.51. p. 20695-0700.] | [http://www.pnas.org/content/early/2011/11/29/1117715108 Phoolcharoen, Waranyoo, John M. Dye, et al. "A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge". ''Proceedings of the National Academy of Sciences of the United States of America''. 2011. Volume 180.51. p. 20695-0700.] | ||
[http://www.nature.com/srep/2012/121115/srep00811/full/srep00811.html Weingartl, Hana M., Carissa Embury-Hyatt, Charles Nfon, Anders Leung, Greg Smith, and gary Kobinger. "Transmission of Ebola virus from pigs to non-human primates". ''Scientific Reports 2''. 2012.] | [http://www.nature.com/srep/2012/121115/srep00811/full/srep00811.html Weingartl, Hana M., Carissa Embury-Hyatt, Charles Nfon, Anders Leung, Greg Smith, and gary Kobinger. "Transmission of Ebola virus from pigs to non-human primates". ''Scientific Reports 2''. 2012.] | ||
Revision as of 22:06, 25 March 2013
Introduction
Double brackets: [[
Filename: [[1]]
Thumbnail status: |thumb|
Pixel size: |300px|
Placement on page: |right|
Legend/credit:
Closed double brackets: ]]
Other examples:
Bold
Italic
Subscript: H2O
Superscript: Fe3+
The Ebola virus is Ebola is considered a Biosafety level 4 (BSL-4) agent. This indicates that it is among the most threatening agents that exist in the world today. Agents within this category pose severe threats to human health and can be fatal due to the lack of treatments and/or available vaccines.
Ebola Virus Structure
Include some current research in each topic, with at least one figure showing data.
Ebola Transmission
Include some current research in each topic, with at least one figure showing data.
Ebola Treatments
Include some current research in each topic, with at least one figure showing data.
Conclusion
Overall paper length should be 3,000 words, with at least 3 figures.
References
Edited by (Victoria Rose Gawlik), a student of Nora Sullivan in BIOL187S (Microbial Life) in The Keck Science Department of the Claremont Colleges Spring 2013.